It has raised funds from Bono, The Edge and Salesforce CEO Marc Benioff, and secured a line of credit from the European Investment Bank. However, amid mounting losses, auditors for Nuritas expressed “significant doubt on the company’s ability to continue as a going concern” in the 2020 accounts for the biotech company. Since then the company has bounced back. In November, it closed a massive $45 million funding round to help accelerate its global expansion. The investment, which brought total funding to $75 million, was led by Chicago-based Cleveland Avenue and included backing from Grosvenor’s Wheatsheaf Group, the European Circular…

Read on for just €1

For a limited time, get your first month for €1 and unlock full access to The Currency and The Wall Street Journal – two premium memberships, one subscription.

Subscribe

Cancel at any time.

Are you already a member? .